Log In
BCIQ
Print this Print this
 

Staybla, Uritos, imidafenacin (KRP-197) (ONO-8025)

  Manage Alerts
Collapse Summary General Information
Company Ono Pharmaceutical Co. Ltd.
DescriptionSelective antagonist of the M1 and M3 subtypes of the muscarinic acetylcholine receptor
Molecular Target Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) ; Muscarinic acetylcholine receptor M3 (CHRM3) (HM3)
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation
PartnerKyorin Pharmaceutical Co. Ltd.;
LG Life Sciences Ltd.;
R-Pharm CJSC;
Synmosa Biopharma Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today